Crossmark

Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool

Crossref DOI link: https://doi.org/10.1186/s40364-022-00383-3

Published Online: 2022-05-25

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Marañón, Patricia

Fernández-García, Carlos Ernesto

Isaza, Stephania C.

Rey, Esther

Gallego-Durán, Rocío

Montero-Vallejo, Rocío

de Cía, Javier Rodríguez

Ampuero, Javier

Romero-Gómez, Manuel

García-Monzón, Carmelo

González-Rodríguez, Águeda http://orcid.org/0000-0003-2851-2318
Funding

Funding for this research was provided by:

Gilead Sciences (GLD18/00151, GLD18/00151)

Instituto de Salud Carlos III (CP14/00181)

Fondo Europeo para el Desarrollo Regional

CIBEREHD

CIBERDEM
License Information

Text and Data Mining valid from 2022-05-25

Version of Record valid from 2022-05-25
More Information

Article History

Received: 13 April 2022

Accepted: 10 May 2022

First Online: 25 May 2022

Declarations

:

: This study was performed in agreement with the Declaration of Helsinki, and with local and national laws. The Human Ethics Committee of the Hospital Universitario Santa Cristina (reference, PI-688A) and Hospital Universitario Virgen del Rocío (reference, C.I. 0359-N-15) approved the study procedures, and all participants signed an informed written consent before inclusion in the study.

: Not applicable.

: All authors have declared that no competing interest exists.

Document is current

Any future updates will be listed below